Key Takeaways for Illumina Stock as of August 2026
- Broad-Based Beat: Illumina posted Q2 revenue of $1.159B, topping the $1.13075B Street estimate by 2.50%, while adjusted EPS of $1.31 beat by 6.77% and grew 10.08% YoY.
- Guidance Raised: Management lifted full-year ROW organic revenue growth guidance above 5%, up from a prior 2% to 4% range, and raised EPS guidance to $5.30 to $5.40.
- Clinical Consumables Reacceleration: Clinical sequencing consumables grew 15% ex-China, with the US/Canada region topping 20% growth, pushing the full-year clinical consumables guide up to ~15% growth.
Illumina stock just cleared a beat-and-raise quarter built on clinical demand, not one-time items. See the full breakdown for free on TIKR for free →.
Illumina Stock Rides a Clinical Consumables Wave to a Raised Full-Year Guide
Illumina (ILMN) reported its fastest revenue growth since CEO Jacob Thaysen took the helm, with second-quarter revenue of $1.159 billion, up 9.5% year over year on a reported basis and 6.5% organically, released after market close on July 30, 2026. That top-line strength flowed straight through the P&L. Non-GAAP operating margin came in at 22.5%, and adjusted EPS of $1.31 grew 10% year over year, both ahead of guidance despite higher freight and memory costs.
The growth engine sits in clinical markets, which now make up roughly 65% of sequencing consumables revenue. Clinical consumables grew 15% ex-China, with the US/Canada region running above 20%, while sequencing gigabase output on connected instruments climbed more than 30% year over year. That volume is landing on a rapidly converting installed base: 78% of clinical sequencing volume now runs on the NovaSeq X platform, and Illumina placed more than 95 NovaSeq X units in the quarter alone, pushing instruments revenue up 31% year over year to $125 million.
Some investors have questioned whether that placement pace signals a near-term ceiling on clinical adoption. Thaysen rejected that framing directly on the Q2 earnings call: “Talking about the clinical cliff, I agree, it’s not a cliff. It’s a wave, and we are surfing it as you are saying.” That confidence shows up in the numbers: management raised full-year ROW organic revenue growth guidance to above 5%, up from a prior 2% to 4% range, and lifted full-year EPS guidance to $5.30 to $5.40, an 11% increase at the midpoint.
Not every segment is riding that wave. Research and applied consumables fell 7% on a ROW basis as academic customers stayed cautious on funding, though the segment posted 9% sequential growth that Thaysen called too early to label a recovery. Sequencing services and other revenue grew 14%, aided by early Billion Cell Atlas data revenue now flowing from six biopharma partners.
With clinical consumables carrying the load and instrument placement growth already elevated, Illumina now points toward high single-digit revenue growth in 2027 as the expanding NovaSeq X base converts into recurring consumables pull-through.
Illumina just raised its clinical consumables guide to mid-teens growth on a NovaSeq X installed base expanding faster than expected. Dig into the segment data on TIKR for free →.
TIKR Values Illumina Stock at $251, Pricing In the Clinical Growth Wave
TIKR’s mid-case model values Illumina at $251 by December 2030, implying 22% total return from the current price of $205, or 5% annualized over the next four years.
That annualized return sits well below the double-digit growth Illumina just delivered in EPS and clinical consumables, positioning Illumina stock as a steadier compounder in the model rather than a re-rating story. The gap between near-term momentum and the model’s modest annualized pace reflects a valuation built on patience, not on a repeat of this quarter’s 10% EPS growth every year through 2030.
The target is reachable because the dynamics behind this quarter’s beat are structural rather than one-time: 78% clinical volume conversion to NovaSeq X, a clinical consumables guide raised to mid-teens growth, and management’s own line of sight to high single-digit revenue growth in 2027 as recently placed instruments mature into full consumables pull-through.
TIKR’s model puts Illumina stock’s target at $251, a 22% total return from today’s price. Pull up the full valuation build on TIKR for free →.
Should You Invest in Illumina, Inc.?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up Illumina, Inc. stock and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track Illumina, Inc. alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Access Professional Tools to Analyze ILMN stock on TIKR for Free →
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
